Boxer Capital’s Puma Biotechnology PBYI Stock Holding History

Boxer Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-100,000	Closed	-$12M	–	27
2017 Q3	$12M	Hold	100,000	–	–	2.73%	12
2017 Q2	$8.74M	Hold	100,000	–	–	2.08%	12
2017 Q1	$3.72M	Buy	+100,000	New	+$3.65M	0.81%	18

Other funds holding PBYI

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Boxer Capital's PBYI Position: Q4 2017 in Review

Boxer Capital sold out of Puma Biotechnology (PBYI) in Q4 2017, closing a stake of 100,000 shares — an estimated $12M sold.

Boxer Capital first reported a position in PBYI in Q1 2017 and held it in 3 quarters. The position peaked at $12M in Q3 2017. 203 funds tracked by Wall St. Rank hold PBYI as of Q4 2017.

Boxer Capital reported no remaining Puma Biotechnology position as of Q4 2017 after selling out during the quarter.
Boxer Capital sold 100,000 Puma Biotechnology shares in Q4 2017, an estimated $12M.
Boxer Capital first reported a position in Puma Biotechnology in Q1 2017 and held it in 3 quarters.
Boxer Capital's Puma Biotechnology position peaked at $12M in Q3 2017.
203 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2017.

Based on Boxer Capital's 13F filing for Q4 2017, filed 14 Feb 2018.